Seattle Genetics

Seattle Genetics’ ADC molecule (antibody-drug conjugate) harnesses the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells while reducing many of the toxic effects of traditional chemotherapy and potentially enhancing antitumor activity. With a very aggressive pipeline, the company’s one approved product, Adcetris, targets Hodgkin and non-Hodgkin lymphoma.

Access is challenged each year to develop a message-focused traffic builder for Seattle Genetics. The one pictured here features Rubik’s cubes.


face to face marketing strategies